Two days ago the Health and Social Care Information Centre published its statistics on the use of NICE-approved medicines yesterday.
The Telegraph also carried a comment article from the Rarer Cancer Foundation: http://www.telegraph.co.uk/health/nhs/10588475/Regulator-needs-to-act-to-stop-endemic-postcode-lottery.html
Andrew Wilson, Chief Executive Officer of the Rarer Cancers Foundation argues:
– The bar for NICE recommendation is very high – it is imperative that when NICE approves a medicine that it gets used appropriately
– The variation between actual and expected levels of usage and between usage in different providers is worrying and needs explaining
– The NHS needs to stop dismissing the factors underpinning variation as ‘complex’ and start explaining to patients and the public why variation happens
– Implementation of guidance should be made a key part of the hospital inspection process
The Rarer Cancers Foundation | Telephone: 0208 692 2910 | Mobile: 07973118290 | http://www.rarercancers.org.uk (includes less common cancers)